These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 17087858)

  • 1. Advanced glycation end products and vascular structure and function.
    Soldatos G; Cooper ME
    Curr Hypertens Rep; 2006 Dec; 8(6):472-8. PubMed ID: 17087858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diabetes and advanced glycation endproducts.
    Vlassara H; Palace MR
    J Intern Med; 2002 Feb; 251(2):87-101. PubMed ID: 11905595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Linking RAGE and Nox in diabetic micro- and macrovascular complications.
    Koulis C; Watson AMD; Gray SP; Jandeleit-Dahm KA
    Diabetes Metab; 2015 Sep; 41(4):272-281. PubMed ID: 26323666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RAGE mediates accelerated diabetic vein graft atherosclerosis induced by combined mechanical stress and AGEs via synergistic ERK activation.
    Li Y; Liu S; Zhang Z; Xu Q; Xie F; Wang J; Ping S; Li C; Wang Z; Zhang M; Huang J; Chen D; Hu L; Li C
    PLoS One; 2012; 7(4):e35016. PubMed ID: 22496883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced glycation end products (AGEs) and diabetic vascular complications.
    Yamagishi S; Nakamura K; Imaizumi T
    Curr Diabetes Rev; 2005 Feb; 1(1):93-106. PubMed ID: 18220586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atherosclerosis and diabetes: the RAGE connection.
    Schmidt AM; Stern D
    Curr Atheroscler Rep; 2000 Sep; 2(5):430-6. PubMed ID: 11122775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High intake of dietary advanced glycation end-products is associated with increased arterial stiffness and inflammation in subjects with type 2 diabetes.
    Di Pino A; Currenti W; Urbano F; Scicali R; Piro S; Purrello F; Rabuazzo AM
    Nutr Metab Cardiovasc Dis; 2017 Nov; 27(11):978-984. PubMed ID: 28958695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of advanced glycation end products (AGEs) signaling in coronary artery disease.
    Kosmopoulos M; Drekolias D; Zavras PD; Piperi C; Papavassiliou AG
    Biochim Biophys Acta Mol Basis Dis; 2019 Mar; 1865(3):611-619. PubMed ID: 30611860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Glycation Angle to Look into the Diabetic Vasculopathy: Cause and Cure.
    Ahmad S; Siddiqui Z; Rehman S; Khan MY; Khan H; Khanum S; Alouffi S; Saeed M
    Curr Vasc Pharmacol; 2017; 15(4):352-364. PubMed ID: 28356033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A possible involvement of crosstalk between advanced glycation end products (AGEs) and asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor in accelerated atherosclerosis in diabetes.
    Yamagishi S; Ueda S; Okuda S
    Med Hypotheses; 2007; 69(4):922-4. PubMed ID: 17368960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications.
    Wautier JL; Wautier MP; Schmidt AM; Anderson GM; Hori O; Zoukourian C; Capron L; Chappey O; Yan SD; Brett J
    Proc Natl Acad Sci U S A; 1994 Aug; 91(16):7742-6. PubMed ID: 8052654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperglycemia and the pathobiology of diabetic complications.
    Aronson D
    Adv Cardiol; 2008; 45():1-16. PubMed ID: 18230953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular mechanisms of diabetic angiopathy--clues for innovative therapeutic interventions.
    Bierhaus A; Ziegler R; Nawroth PP
    Horm Res; 1998; 50 Suppl 1():1-5. PubMed ID: 9676989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RAGE biology, atherosclerosis and diabetes.
    Barlovic DP; Soro-Paavonen A; Jandeleit-Dahm KA
    Clin Sci (Lond); 2011 Jul; 121(2):43-55. PubMed ID: 21457145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new dark side of the Maillard's products.
    Wautier JL
    Diabetes Metab; 2003 Feb; 29(1):86-7. PubMed ID: 12629454
    [No Abstract]   [Full Text] [Related]  

  • 16. [Endothelial dysfunction in type 1 diabetes].
    Bertoluci MC; Cé GV; da Silva AM; Puñales MK
    Arq Bras Endocrinol Metabol; 2008 Mar; 52(2):416-26. PubMed ID: 18438553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetes and vascular disease: basic concepts of nitric oxide physiology, endothelial dysfunction, oxidative stress and therapeutic possibilities.
    Capellini VK; Celotto AC; Baldo CF; Olivon VC; Viaro F; Rodrigues AJ; Evora PR
    Curr Vasc Pharmacol; 2010 Jul; 8(4):526-44. PubMed ID: 19485895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced glycation end products in diabetes-associated atherosclerosis and renal disease: interventional studies.
    Jandeleit-Dahm KA; Lassila M; Allen TJ
    Ann N Y Acad Sci; 2005 Jun; 1043():759-66. PubMed ID: 16037303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roles of the AGE-RAGE system in vascular injury in diabetes.
    Yamamoto Y; Yamagishi S; Yonekura H; Doi T; Tsuji H; Kato I; Takasawa S; Okamoto H; Abedin J; Tanaka N; Sakurai S; Migita H; Unoki H; Wang H; Zenda T; Wu PS; Segawa Y; Higashide T; Kawasaki K; Yamamoto H
    Ann N Y Acad Sci; 2000 May; 902():163-70; discussion 170-2. PubMed ID: 10865836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roles of advanced glycation endproducts (AGE) and receptor for AGE on vascular smooth muscle cell growth.
    Wang R; Kudo M; Yokoyama M; Asano G
    J Nippon Med Sch; 2001 Dec; 68(6):472-81. PubMed ID: 11744927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.